Listen on the go
CORRECT!
Next question
touchNEUROLOGY touchNEUROLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Epilepsy

    EUROPEAN PARTNER

    An Introduction to Epilepsy

    Epilepsy is one of the most common neurological disorders, affecting around 50 million people worldwide. Advances in epilepsy imaging and treatment (e.g. ablative and neurostimulation procedures, and new antiepileptic drugs) have decreased seizure frequency and severity. Yet unmet needs remain with approximately 30% of people with epilepsy refractory to pharmacotherapies. Novel therapeutic targets include AMPA receptors, potassium channels and synaptic vesicle protein 2A. Ongoing developments and improved understanding of the genetics of epilepsy subtypes may provide patient-specific solutions.

    Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from our journal touchREVIEWS in Neurology. This is complimented by a range of educational activities developed in collaboration with our leading expert faculty.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Epilepsy Content

    Alzheimer's Disease and Dementia, Brain Trauma, COVID-19, Epilepsy, Headache Disorders, Neurodegenerative Diseases, Movement Disorders, Multiple Sclerosis, Neuroimmunology, Neurological Oncology, Neurometabolic Disease, Neuromuscular Diseases, Neuropathic Pain, Stroke, Neurosurgery, Paediatric Neurology, Parkinson's Disease, Psychiatric Disorders, Sleep Disorders, Central Nervous Disorders, Neuroradiology
    BrainGPT: Advancing neuroscientific research with AI

    In this episode, we’re joined by Bradley Love, Professor of Cognitive and Decision Sciences at UCL, ELLIS fellow, and creator of BrainGPT. We discuss how this large language model is poised to assist researchers in advancing their work.

    Epilepsy
    New guidelines for epilepsy and pregnancy: AAN, AES and SMFM collaboration

    A new guideline has been issued to assist neurologists and clinicians in selecting the best anti-seizure medications for people with epilepsy who may become pregnant. Published in Neurology, the guideline is a collaboration between the American Academy of Neurology (AAN), the American Epilepsy Society (AES) and the Society for Maternal-Fetal Medicine (SMFM), with endorsement from the Child Neurology Society. It updates parts of the 2009 AAN and AES guidelines regarding birth malformations and child development in children born to people with epilepsy.

    Epilepsy
    Mapping a legacy in epilepsy: The career journey of Prof. Ruben Kuzniecky

    We're excited to launch a new series of expert Q&As with our editorial board, highlighting their career milestones, top advice, and future insights in their specialties. In this first interview we are honoured to welcome Dr Ruben I Kuzniecky, MD, an internationally recognized leader in epilepsy, epilepsy surgery and neuroimaging.

    Epilepsy
    Exploring Cellular Mechanisms and Restorative Cell-based Therapeutics for Epilepsy
    Lily H Kim, Muhammad Ammar Haider, Kevin K Kumar

    touchREVIEWS in Neurology. 2024;20(2):2-5

    Affecting over 70 million patients worldwide, epilepsy is a chronic neurological disorder characterized by intermittent bursts of hyper-synchronous neuronal discharges.1 The manifestations are variable but reflective of the unique milieu and biology of epileptogenic foci.2 Pharmacological treatment with antiepileptic drugs (AEDs) is supportive only and, for up to 30% of patients, is inadequate in preventing seizures.3 While surgical […]

    touchEXPERT BRIEFING
    Improving disease screening in Lennox-Gastaut syndrome
    For HCPs in: USA
    View Time: 19 mins Sponsored content

    Watch four leading experts discuss the Refractory Epilepsy Screening Tool for Lennox-Gastaut syndrome (REST-LGS) and its diagnostic and treatment implications.

     

    VV-MED-66609
    Date of Preparation: January 2024
    Epilepsy
    Acute Management of Seizure Clusters and Prolonged Seizures: A Review of Rescue Therapies
    Sadie Goodman, Gabriel Chan, Nisali A Gunawardane

    touchREVIEWS in Neurology. 2024;20(1):4-9

    Rescue medications are an important part of the treatment regimen for patients with intractable epilepsy, specifically those who experience seizure clusters or prolonged seizure episodes. Rescue medications are prescribed to end seizure activity quickly and effectively in order to prevent further seizure-related morbidities and prevent seizure recurrence. An ideal rescue medication is stable at room […]

    Epilepsy, Headache Disorders, Multiple Sclerosis, Neuroimmunology, Neuromuscular Diseases, Parkinson's Disease
    Developed by Touch
    Highlights from EAN 2023!
    Watch Time: 2 mins

    Epilepsy
    Developed by Touch
    Jacqueline French, AAN 2023: XEN1101, a novel potassium channel modulator for the treatment of focal epilepsy
    Watch Time: 03:52

    In this interview with touchNEUROLOGY, Prof. Jacqueline French (Comprehensive Epilepsy Center, New York University, New York, NY, US) discusses the needs of adults with focal epilepsy and the mechanisms of action of XEN1101, a novel, potent, selective Kv7.2/7.3 potassium channel. The abstract entitled “XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, […]

    Epilepsy
    Developed by Touch
    Jacqueline French, AAN 2023: X-TOLE phase 2b open-label extension trial of XEN1101 in focal epilepsy – interim data
    Watch Time: 07:57

    The randomized, double-blind, placebo-controlled phase IIb study X-TOLE (NCT03796962) is investigating the efficacy of XEN1101, a novel potassium channel modulator, in adults with focal epilepsy.   In this interview with touchNEUROLOGY, Prof. Jacqueline French (Comprehensive Epilepsy Center, New York University, New York, NY, US) discusses this clinical trial and the outcomes of its open-label extension.  The […]

    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchNEUROLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup